Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation

Francesco Iuliano, MD, Eleonora Iuliano, MD, Marco Rossi, MD

Blood (2018) 132 (Supplement 1): 2449.

https://doi.org/10.1182/blood-2018-99-118518

Published: 2018

Journal Articles

Assisted Administration of Subcutaneous Rituximab to the Patient's Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety

Francesco Iuliano, MD, Eleonora Iuliano, MD, Marco Rossi, MD

Blood (2018) 132 (Supplement 1): 5869.

https://doi.org/10.1182/blood-2018-99-118756

Published: 2018

Journal Articles

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Maria Luci, MD, Maria Aquila Santoro, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2016) 128 (22): 1269.

https://doi.org/10.1182/blood.V128.22.1269.1269

Published: 2016

Journal Articles

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Maria Aquila Santoro, MD, Angelo Pomillo, MD, Maria Luci, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2016) 128 (22): 4926.

https://doi.org/10.1182/blood.V128.22.4926.4926

Published: 2016

Journal Articles

Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Maria Luci, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Elisabetta Abruzzese

Blood (2014) 124 (21): 5012.

https://doi.org/10.1182/blood.V124.21.5012.5012

Published: 2014

Journal Articles

Effectiveness and Safety of Low Dose Eltrombopag Twice Weekly in ITP Patients That Achieved CR after 50mg Daily Standard Dose

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Maria Luci, MD, Elisabetta Abruzzese

Blood (2014) 124 (21): 2788.

https://doi.org/10.1182/blood.V124.21.2788.2788

Published: 2014

Journal Articles

Assisted Administration Of Subcutaneous 5-Azacytidine to The Patient's Home. Significant Reduction Of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together With a Total Adhesion To The Treatment Schedule and Same Safety

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Maria Luci, MD, Gianluca Cervo

Blood (2013) 122 (21): 5587.

https://doi.org/10.1182/blood.V122.21.5587.5587

Published: 2013

Journal Articles

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Cirino Botta, MD, Marco Rossi, MD, Maria Rita Pitari, PhD, Annamaria Gullà, MD, Teresa Del Giudice, MD, Eugenio Morelli, MD, Eleonora Iuliano, MD, Emanuela Altomare, PhD, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Pierpaolo Correale, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 4489.

https://doi.org/10.1182/blood.V122.21.4489.4489

Published: 2013

Journal Articles

Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease

Maria Rita Pitari, PhD, Marco Rossi, MD, Cirino Botta, MD, Eugenio Morelli, MD, Annamaria Gullà, MD, Eleonora Iuliano, MD, Teresa Del Giudice, MD, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Fortunato Morabito, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 683.

https://doi.org/10.1182/blood.V122.21.683.683

Published: 2013

Journal Articles

Platelet Kinetic Study (PKS) May Early Identify a Subset of Patients with Immune Thrombocytopenia (ITP) Probably Cured by Romiplostim. Two Years Follow-up

Francesco Iuliano, MD, Alessia Perricelli, MD, Eleonora Iuliano, MD, Stefania Infusino, PhD, Angelo Pomillo, MD, Maria Luci, MD, Filippo Barbano, MD

Blood (2012) 120 (21): 1099.

https://doi.org/10.1182/blood.V120.21.1099.1099

Published: 2012

Journal Articles

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

Marco Rossi, MD, Maria Rita Pitari, PhD student, Nicola Amodio, PhD, Maria Teresa Di Martino, PhD, Emanuela Leone, PhD, Francesco Conforti, MD, Francesco Maria Paolino, PhD student, Cirino Botta, MD, Teresa Del Giudice, MD, Eleonora Iuliano, MD, Manlio Ferrarini, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2012) 120 (21): 3960.

https://doi.org/10.1182/blood.V120.21.3960.3960

Published: 2012

NARROW

Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation

Assisted Administration of Subcutaneous Rituximab to the Patient's Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP)

Effectiveness and Safety of Low Dose Eltrombopag Twice Weekly in ITP Patients That Achieved CR after 50mg Daily Standard Dose

Assisted Administration Of Subcutaneous 5-Azacytidine to The Patient's Home. Significant Reduction Of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together With a Total Adhesion To The Treatment Schedule and Same Safety

Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo

Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease

Platelet Kinetic Study (PKS) May Early Identify a Subset of Patients with Immune Thrombocytopenia (ITP) Probably Cured by Romiplostim. Two Years Follow-up

Mir-29b Negatively Regulates Osteoclastic Cell Differentiation and Function: Implications for the Treatment of Multiple Myeloma-Related Bone Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only